AlphaMadera's AlphaVal page computes Krystal Biotech, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag KRYS as undervalued, fairly valued, or overvalued.

What is Krystal Biotech, Inc.'s fair value?

Fair value for KRYS is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value KRYS?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from KRYS's most recent reported fundamentals.

KRYS - Krystal Biotech, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $336.40 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Moderate

Trading 35.3% above fair value

Current Price $375.07

Bear Case $165.30 55.9% downside ($165.30 - $375.07) / $375.07 = -55.9% 12% stage 1 growth, 11% discount

Fair Value $277.17 26.1% downside ($277.17 - $375.07) / $375.07 = -26.1% 20% stage 1 growth, 11% discount

Bull Case $417.66 11.4% upside ($417.66 - $375.07) / $375.07 = 11.4% 26% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

20.0%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (20% base case)

Terminal Value % of EV 46%

Implied Market Multiple 69.2x

Market is pricing in (growth) 25.5% vs our 20.0% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $336.40 from 17 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $277.17 per share.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions